News

Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management-02-01-2017
Volume12
Issue 2

WuXi AppTec Acquires HD Biosciences

WuXi AppTech acquired HD Biosciences, a preclinical drug-discovery-focused CRO.

On Jan. 19, 2017 WuXi AppTec announced the acquisition of the biology-focused preclinical drug discovery contract research organization (CRO), HD Biosciences (HDB). After completion of the acquisition, HDB will become a wholly-owned subsidiary of WuXi. The company did not disclose the financial terms of the acquisition. 

HBD is headquartered in Shanghai and has operating facilities in Beijing and San Diego, CA. HBD offers? plate-based pharmacology and screening capabilities, hit identification, lead discovery, and in vivo pharmacology, among other services. In a statement, WuXi said the acquisition will further strengthen its R&D capability from target validation to lead discovery and optimization, expanding WuXi's open-access enabling service platform.

Source: WuXi AppTec

 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
Understanding the Operational Impacts of the 15% US-EU Pharma Tariff Cap
Dave Miller, PhD, Chief Scientific Officer, AustinPx